ABL Diagnostics announces the release of its DeepChek®-HPV Assay, to be used for Human Papillomavirus screening, genotyping, and discrimination through sequencing.

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the release of its DeepChek®-HPV Assay for the screening, the genotyping, and the discrimination of the Human Papillomavirus (“HPV”). The assay uses an innovative design which allows

ABL Diagnostics announces the release of its DeepChek®-HPV Assay, to be used for Human Papillomavirus screening, genotyping, and discrimination through sequencing. Read More »

ABL Diagnostics announces new releases of its DeepChek®, ViroScore® and MicrobioChek® software platforms for microbiology clinical genotyping

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the release of new versions of its CE-IVD (In Vitro Diagnostics) DeepChek® and ViroScore® software applications (v3.30.115-ivdr). Tailored to analyze Next Generation Sequencing (NGS) and Capillary Electrophoresis

ABL Diagnostics announces new releases of its DeepChek®, ViroScore® and MicrobioChek® software platforms for microbiology clinical genotyping Read More »

ABL DIAGNOSTICS INTRODUCING CRISPRCHEK – A NEW LINE OF ASSAYS USING THE CRISPR TECHNOLOGY

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce a major evolution of its research & development activities with the design of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology. With the intent

ABL DIAGNOSTICS INTRODUCING CRISPRCHEK – A NEW LINE OF ASSAYS USING THE CRISPR TECHNOLOGY Read More »

ABL DIAGNOSTICS EXPANDS ITS HIV GENOTYPING ASSAYS OFFERING

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce the expansion of its HIV genotyping menu of applications with the release of a new revolutionary assay, DeepChek® Assay HIV-1 Full PR/RT/INT Drug Resistance. The company keeps innovating

ABL DIAGNOSTICS EXPANDS ITS HIV GENOTYPING ASSAYS OFFERING Read More »

ABL Diagnostics expands its commercial network and collaborations to offer unique Sanger & NGS based microbiology genotyping assays and software worldwide.

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the expansion of its network of exclusive distributors, able to offer the DeepChek® technology to laboratories willing to implement microbiology applications like HIV, SARS-CoV-2, Tuberculosis, Cytomegalovirus, Viral

ABL Diagnostics expands its commercial network and collaborations to offer unique Sanger & NGS based microbiology genotyping assays and software worldwide. Read More »

ABL Diagnostics: A partner of choice for your scientific projects

ABL Diagnostics: A partner of choice for your scientific projects APHP (Assistance Publique Hôpitaux de Paris) // France Epidemiological and Molecular evolution of the HIV-1 CRF94: Birth of CRF 132  ♦♦♦ CHU Caen-Normandie // France Interest of HIV-1 Next-Generation Sequencing in a diagnosis laboratory in France ♦♦♦ CHU Amiens-Picardie // France Whole Genome Sequencing of

ABL Diagnostics: A partner of choice for your scientific projects Read More »

Scroll to Top